Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer Journal Article
| Authors: | Kalinsky, K.; Ho, A.; Barker, C. A.; Seidman, A. |
| Article Title: | Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer |
| Abstract: | Treating breast cancer patients concurrently with chemotherapy and radiation is a potentially attractive approach. The goal is to develop strategies that enhance the effects of each modality while minimizing toxicity. Most data evaluating the role of simultaneous therapy have been generated from small phase 1 and 2 trials. As few prospective, randomized controlled trials have been performed in this area, generating definitive conclusions regarding the efficacy and toxicity from combined therapy remains difficult. This article reviews the current literature on the benefits and toxicities of concurrent radiation with cytotoxic chemotherapy, as well as with novel biologic agents such as monoclonal antibodies, tyrosine kinase inhibitors, and heat shock protein antagonists. Because the appropriate use of concurrent radiation with chemotherapy and biologic agents continues to evolve, we also highlight future and ongoing trials evaluating this treatment option. Copyright © 2009 by Current Medicine Group LLC. |
| Keywords: | cancer chemotherapy; treatment outcome; treatment response; unclassified drug; overall survival; clinical trial; drug tolerability; neutropenia; review; bevacizumab; cytotoxic agent; doxorubicin; fluorouracil; drug efficacy; drug safety; drug withdrawal; hypertension; multimodality cancer therapy; skin toxicity; treatment duration; skin manifestation; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; cancer radiotherapy; disease free survival; methotrexate; drug megadose; treatment indication; carboplatin; drug eruption; liver toxicity; multiple cycle treatment; pain; breast cancer; anemia; mastectomy; tumor volume; blood toxicity; esophagitis; leukopenia; mucosa inflammation; neuropathy; stomatitis; cyclophosphamide; steroid; continuous infusion; docetaxel; irinotecan; monoclonal antibody; protein tyrosine kinase inhibitor; asthenia; coughing; drug hypersensitivity; dyspnea; febrile neutropenia; hyperglycemia; loading drug dose; pneumonia; lymphedema; chemotherapy induced emesis; dysphagia; skin exfoliation; disease severity; thorax pain; add on therapy; radiation dose fractionation; contrast enhancement; cardiotoxicity; mitoxantrone; brain metastasis; hyperpigmentation; limb pain; 17 demethoxy 17 (2 dimethylaminoethylamino)geldanamycin; nausea and vomiting; epirubicin; skin discoloration; telangiectasia; taxane derivative; drug half life; biological therapy; trastuzumab; navelbine; drug substitution; anthracycline; alopecia; intraductal carcinoma; lapatinib; gadolinium texaphyrin; heat shock protein antagonist; protein inhibitor; breast atrophy; breast edema; pseudoporphyria; radiation dermatitis; radiation pneumonia; radiosensitization; repeated drug dose; sclera disease; subcutaneous fibrosis; urine discoloration |
| Journal Title: | Current Breast Cancer Reports |
| Volume: | 1 |
| Issue: | 1 |
| ISSN: | 1943-4588 |
| Publisher: | Springer |
| Date Published: | 2009-03-01 |
| Start Page: | 29 |
| End Page: | 41 |
| Language: | English |
| DOI: | 10.1007/s12609-009-0005-5 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work